3Nosadini R,Abaterusso C,Dalla VM,et al.Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus[J].Nephrol Dial Transplant,1998,13:44-45.
4The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high risk hyertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic(ALLHAT)[J].JAMA,2002,288:2981-2997.
5Julius S,Kjeldsen SE,Weber M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:The VALUE randomised trial[J].Lancet,2004,363(9426):2022-2031.
6Bjorn D.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):A multicentre randomised controlled trial[J].Lancet,2005,366(9489):895-906.
7Neil RP.Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm(ASCOT-BPLA)[J].Lancet,2005,366(9489):907-913.
8Zannad F,Matzinger A,Larché J.Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists[J].Hypertens,1996,9(7):633-643.
9Zanchetti A.Trough:Peak ratio of the blood pressure response to dihydropyridine calcium antagonists.Italian Nifedipine GITS Study Group[J].Hypertens,1994,12(8):S97-106.
10Pedersen OL,Mancia G,Pickering T,et al.Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment:A VALUE substudy[J].Hypertens,2007,25(3):700-712.
